logo
Plus   Neg
Share
Email

Genentech's Late-stage Study On Aggressive Leukemia Meets Primary Endpoints

Genentech, a member of the Roche Group (RHHBY), said that the late-stage VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate.

The study showed Venclexta plus azacitidine helped people with the most common type of aggressive leukemia in adults live longer compared to azacitidine alone.

Safety for Venclexta plus azacitidine appeared consistent with the known safety profile of these medicines.

Venclexta is being developed by AbbVie and Genentech. It is jointly commercialized by the companies in the United States and commercialized by AbbVie outside of the United States.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
In view of an expected growth in online shopping in the upcoming holiday season, Walmart announced its plan to hire more than 20,000 seasonal associates in its eCommerce fulfillment centers across the country. The company offers a starting hourly rate ranging from $15.75 up to $23.75 based on location, position and schedule. Tour operator TUI AG Tuesday said Summer 2020 and Winter 2020/21 capacity reduced as a result of recent volatile changes in travel restrictions amid Covid-19 pandemic. The company further announced the launch of Global Realignment Programme, aiming to permanently reduce overhead cost base by 30%. The program potentially impacts 8,000 roles. Home improvement retailer Lowe's Companies Inc. plans to install pickup lockers at all U.S. stores aiming to improve contactless delivery for online buyers amid worsening Covid-19 spread. The "Buy Online Pickup in Store" self-service lockers at its more than 1,700 stores will be available by the end of March 2021. In most major metro markets, the online pickup option will be installed by Thanksgiv
Follow RTT